ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit claims that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - Investors reportedly suffered damages when the true details about the company's financial priorities became public [4].